Ferric citrate  (Synonyms: 柠檬酸铁; Iron(III) citrate; Zerenex)

Ferric citrate (Iron(III) citrate), an orally active iron supplement, is an efficacious phosphate binder. Ferric citratee can be used for iron deficiency anemia and chronic kidney disease (CKD) research^[1][2].

Ferric citrate (Iron(III) citrate; 1 mM; 24 hours) significantly induces CM cell death^[1].
Ferric citrate (Iron(III) citrate; 0.1 mM, 1 mM, 2 mM; 24 hours) increases ROS generation in cardiomyocyte (CM) cells in a dose-dependent manner^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Here we compared the effects of Ferric citrate (25 μg/g) administration versus a mineral sufficient control diet using the Col4a3 knockout mouse model of progressive CKD and age-matched wild-type mice. Ferric citrate is given to knockout mice for four weeks beginning at six weeks of age when they had overt chronic kidney disease (CKD), or for six weeks beginning at four weeks of age when they had early CKD. Ferric citrate rescues iron deficiency and anemia in knockout mice regardless of the timing of treatment initiation, and circulating levels and bone expression of FGF23 are reduced. Ferric citrate also improves cardiac function and significantly improves survival^[3].
Ferric citrate is an efficacious and safe phosphate binder that increases iron stores and reduces intravenous iron and erythropoietin-stimulating agent use while maintaining hemoglobin. Ferric citrate can increase transferrin saturation, serum ferritin, and hemoglobin^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

244.94

C₆H₅FeO₇

3522-50-7

固体

Brown to black

柠檬酸铁；枸橼酸铁；柠檬酸三铁

Room temperature in continental US; may vary elsewhere.

Store at room temperature, keep dry and cool

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用，-20°C储存时，请在1年内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

• [1]. Yuichi Baba, et al. Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes. Am J Physiol Heart Circ Physiol. 2018 Mar 1;314(3):H659-H668.  [Content Brief]

  [2]. Julia B Lewis, et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol. 2015 Feb;26(2):493-503.  [Content Brief]

  [3]. Connor Francis, et al. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease. Kidney Int. 2019 Dec;96(6):1346-1358.  [Content Brief]